FORMULARYWATCH.COM: Keyword Density Checker

Total words: 2965 | 2-word phrases: 756 | 3-word phrases: 860 | 4-word phrases: 908

PAGE INFO

Title	Try to keep the title under 60 characters (15 characters) Formulary Watch
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

ONE WORD PHRASES 441 Words

#	Keyword	Frequency	Density
1	2024	26	5.90%
2	to	24	5.44%
3	for	24	5.44%
4	by	22	4.99%
5	and	21	4.76%
6	fda	21	4.76%
7	the	19	4.31%
8	of	17	3.85%
9	in	15	3.40%
10	formulary	14	3.17%

TWO WORD PHRASES 756 Words

#	Keyword	Frequency	Density
1	by formulary	13	1.72%
2	fda approves	9	1.19%
3	formulary watchmay	9	1.19%
4	by denise	6	0.79%
5	1st 2024	5	0.66%
6	to treat	5	0.66%
7	diabetes and	4	0.53%
8	therapy for	4	0.53%
9	view more	4	0.53%
10	regulatory updates	4	0.53%
11	and behavioral	4	0.53%
12	and ent	4	0.53%
13	drug coverage	4	0.53%
14	breyanzi for	4	0.53%
15	psychiatry and	4	0.53%
16	clinical pharmacology	4	0.53%
17	is a	4	0.53%
18	for a	4	0.53%
19	date for	4	0.53%
20	cancer by	4	0.53%

THREE WORD PHRASES 860 Words

#	Keyword	Frequency	Density
1	by formulary watchmay	8	0.93%
2	by denise myshkomay	4	0.47%
3	cancer by formulary	4	0.47%
4	psychiatry and behavioral	4	0.47%
5	begin submission of	3	0.35%
6	submission of subcutaneous	3	0.35%
7	immunology and ent	3	0.35%
8	approves nonstimulant adhd	3	0.35%
9	approves breyanzi for	3	0.35%
10	fda approves breyanzi	3	0.35%
11	breyanzi for follicular	3	0.35%
12	eisai begin submission	3	0.35%
13	rx to offer	3	0.35%
14	watchmay 29th 2024	3	0.35%
15	guaranteebased pricing model	2	0.23%
16	to offer guaranteebased	2	0.23%
17	by formulary watchjune	2	0.23%
18	diabetes and endocrinology	2	0.23%
19	vaccine by formulary	2	0.23%
20	rsv vaccine by	2	0.23%
21	of subcutaneous leqembi	2	0.23%
22	fda approves nonstimulant	2	0.23%
23	metastatic breast cancer	2	0.23%
24	and older with	2	0.23%
25	and behavioral health	2	0.23%
26	optum rx to	2	0.23%
27	review date for	2	0.23%
28	copd cardiovascular clinical	2	0.23%
29	in patients with	2	0.23%
30	cardiovascular clinical pharmacology	2	0.23%

FOUR WORD PHRASES 908 Words

#	Keyword	Frequency	Density
1	eisai begin submission of	3	0.33%
2	fda approves breyanzi for	3	0.33%
3	begin submission of subcutaneous	3	0.33%
4	breyanzi for follicular lymphoma	2	0.22%
5	the fda has set	2	0.22%
6	lymphoma fda approves breyanzi	2	0.22%
7	to offer guaranteebased pricing	2	0.22%
8	cancer by formulary watchmay	2	0.22%
9	optum rx to offer	2	0.22%
10	media expert interviews medical	2	0.22%
11	biogen eisai begin submission	2	0.22%
12	news media expert interviews	2	0.22%
13	allergy immunology and ent	2	0.22%
14	submission of subcutaneous leqembi	2	0.22%
15	psychiatry and behavioral health	2	0.22%
16	copd cardiovascular clinical pharmacology	2	0.22%
17	endocrinology drug coverage idiopathic	2	0.22%
18	rsv vaccine by formulary	2	0.22%
19	fda approves nonstimulant adhd	2	0.22%
20	pharmacy psychiatry and behavioral	2	0.22%
21	approves nonstimulant adhd medication	2	0.22%
22	approves breyanzi for follicular	2	0.22%
23	rx to offer guaranteebased	2	0.22%
24	subscribe conference conference listing	2	0.22%
25	to treat patients with	2	0.22%
26	news podcasts fda cmece	2	0.22%
27	expert interviews medical world	2	0.22%
28	approved to treat patients	1	0.11%
29	denise myshkomay 21st 2024	1	0.11%
30	yesafili and opuviz are	1	0.11%
31	and opuviz are approved	1	0.11%
32	to complete the new	1	0.11%
33	opuviz are approved to	1	0.11%
34	are approved to treat	1	0.11%
35	treat patients with neovascular	1	0.11%
36	eylea by denise myshkomay	1	0.11%
37	wet agerelated macular degeneration	1	0.11%
38	agerelated macular degeneration macular	1	0.11%
39	macular degeneration macular edema	1	0.11%
40	degeneration macular edema following	1	0.11%

EXTERNAL LINKS

#	URL	Whois	Check
1	https://www.medicalworldnews.com/	Whois	medicalworldnews.com
2	https://twitter.com/Formulary_News	Whois	twitter.com
3	https://www.medicalworldnews.com/	Whois	medicalworldnews.com
4	https://www.gotoper.com/courses/evaluating-the-recent-advancements-in-chronic-kidney-disease-treatment-a-case-based-approach-to-managing-ckd-and-related-comorbidities-qlbc?utm_source=formularywatch&utm_medium=homePage&utm_campaign=cmeDeck	Whois	gotoper.com
5	https://www.gotoper.com/courses/elevating-care-for-pah-applying-recommended-management-approaches-to-maximize-outcomes?utm_source=formularywatch&utm_medium=homePage&utm_campaign=cmeDeck	Whois	gotoper.com
6	https://www.gotoper.com/courses/7th-annual-new-york-cardio-endo-renal-collaborative-ny-cerc-dnbz?utm_source=formularywatch&utm_medium=homePage&utm_campaign=cmeDeck	Whois	gotoper.com
7	https://www.gotoper.com/courses/reel-time-patient-counseling-navigating-the-complex-journey-of-diagnosing-and-managing-fabry-disease?utm_source=formularywatch&utm_medium=homePage&utm_campaign=cmeDeck	Whois	gotoper.com
8	https://www.gotoper.com/courses/expert-illustrations-commentaries-envisioning-novel-therapeutic-approaches-to-managing-anca-associated-vasculitis?utm_source=formularywatch&utm_medium=homePage&utm_campaign=cmeDeck	Whois	gotoper.com
9	https://www.mjhlifesciences.com/ccpa?domain=www.formulatorywatch.com	Whois	mjhlifesciences.com
10	https://twitter.com/Formulary_News	Whois	twitter.com
11	https://www.facebook.com/Formulary/	Whois	facebook.com